N-{(S)-2-[4-(4-benzyloxyphenoxy)phenoxy]-1-methylethyl}acetamide | 1204483-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{(S)-2-[4-(4-benzyloxyphenoxy)phenoxy]-1-methylethyl}acetamide
• 英文别名: N-[(2S)-1-[4-(4-phenylmethoxyphenoxy)phenoxy]propan-2-yl]acetamide
• CAS: 1204483-92-0
• 化学式: C₂₄H₂₅NO₄
• 分子量: 391.467
• InChiKey: ZJBIAYWTYXCKSH-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (S)-2-[4-(4-benzyloxyphenoxy)phenoxy]-1-methylethylamine 、 乙酸酐 生成 N-{(S)-2-[4-(4-benzyloxyphenoxy)phenoxy]-1-methylethyl}acetamide
  参考文献：
  名称：

  Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof

  摘要：

  杂环衍生物，其制备方法，包含这些化合物的药物和其用途。本发明涉及式I的化合物，其中基团R1，R2，R3，R4，W，A，B，D，E，G，L，M，R，T和Y具有所述的含义，并且其生理耐受盐。这些化合物适用于例如治疗代谢综合征，胰岛素抵抗，肥胖和糖尿病。

  公开号：

  US08470841B2

文献信息

• HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF
  申请人：Zoller Gerhard

  公开号：US20110183998A1

  公开（公告）日：2011-07-28

  Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.

  杂环衍生物、其制备方法、包含这些化合物的药物和其用途。本发明涉及式I中的化合物，其中基团R1、R2、R3、R4、W、A、B、D、E、G、L、M、R、T和Y具有所述的含义，并且其生理上可耐受的盐。该化合物适用于例如代谢综合征、胰岛素抵抗、肥胖和糖尿病的治疗。
• NOVEL ALKYLENE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP3059225A1

  公开（公告）日：2016-08-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。 此外，本发明的目的是提供包含该化合物的药物组合物。 式（I）化合物：其中 R1 是取代或未取代的融合芳香杂环等，环 A 是取代或未取代的非芳香碳环等、 -L1-是-O-(CR6R7)m-等，-L2-是-O-(CR6R7)n-等，每个 R6 和 R7 独立地是氢、卤素等，R2 是取代或未取代的烷基，R3 是氢或取代或未取代的烷基，R4 是取代或未取代的烷基羰基等。
• ACC2 INHIBITORS
  申请人：Shionogi & Co., Ltd.

  公开号：EP3670496A2

  公开（公告）日：2020-06-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。此外，本发明的目的是提供一种包含该化合物的药物组合物。 式(I)的化合物： 其中 R1 是取代或未取代的融合芳香杂环等、 环 A 是取代或未取代的非芳香族碳环等、 -L1-是-O-(CR6R7)m-等、 -L2-是-O-(CR6R7)n-等、 每个 R6 和 R7 独立地是氢、卤素等、 R2 是取代或未取代的烷基、 R3 是氢或取代或未取代的烷基、 R4 是取代或未取代的烷基羰基等。
• 9-MEMBERED FUSED RING DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP3279187B1

  公开（公告）日：2021-06-02
• NOVEL ALKYLENE DERIVATIVES
  申请人：SHIONOGI & CO., LTD.

  公开号：US20160257641A1

  公开（公告）日：2016-09-08

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R 1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L 1 - is —O—(CR 6 R 7 )m- etc., -L 2 - is —O—(CR 6 R 7 )n- etc., each R 6 and R 7 are independently hydrogen, halogen etc., R 2 is substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is substituted or unsubstituted alkylcarbonyl etc.